<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Atrial fibrillation: Cardioversion
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Atrial fibrillation: Cardioversion
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Atrial fibrillation: Cardioversion
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gerald V Naccarelli, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Warren J Manning, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bradley P Knight, MD, FACC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brian Olshansky, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James Hoekstra, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 22, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H8701623">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The restoration (cardioversion) to sinus rhythm (SR) from atrial fibrillation (AF) is performed primarily to improve symptoms, but it may also prevent tachycardia-induced cardiomyopathy, facilitate management of heart failure, and reduce the risk of inappropriate shocks in those with implanted defibrillators. This topic will focus on our approach to cardioversion and the efficacy and safety of the two most widely used approaches: electrical (direct current) and pharmacologic cardioversion. Other related topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1069.html" rel="external">
          "Restoration of sinus rhythm in atrial flutter"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H952132725">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In this topic, we are generally referring to cardioversion in stable patients with recently diagnosed symptomatic AF that does not terminate spontaneously.
        </p>
        <p>
         Cardioversion is indicated to improve symptoms and hemodynamic status from AF. Among patients with early AF and who are at high risk for cardiovascular complications, cardioversion with accompanying rhythm control strategy of AF management can reduce cardiovascular death or stroke. Patients who may benefit from rhythm versus rate control are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">
          "Management of atrial fibrillation: Rhythm control versus rate control"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">
          "Management of atrial fibrillation: Rhythm control versus rate control", section on 'Indications for initial rhythm control'
         </a>
         .)
        </p>
        <p>
         Cardioversion is most commonly performed in patients who are expected to have long-term maintenance of sinus rhythm, who are expected to convert to normal sinus rhythm, and are at low risk for cardioversion-associated complications (eg, thromboembolism). These may be patients with persistent AF (ie, lasting &gt;7 days) or even paroxysmal AF, if AF is highly symptomatic and cannot be otherwise controlled. It is also preferred in other patient groups.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term rhythm control
         </strong>
         – Patients who will be placed on long-term antiarrhythmic drugs or who will undergo catheter ablation will have SR restored as the initial part of that process. (See
         <a class="medical medical_review" href="/z/d/html/93920.html" rel="external">
          "Maintenance of sinus rhythm in atrial fibrillation: Catheter ablation versus antiarrhythmic drug therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/949.html" rel="external">
          "Atrial fibrillation: Catheter ablation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-standing
         </strong>
         <strong>
          persistent AF
         </strong>
         – It may be reasonable to attempt to restore SR in patients with long-standing, persistent AF who are symptomatic (or occasionally in patients with presumed permanent AF). An example of the latter is a patient with long-duration AF who now has developed increasing heart failure or worsening cardiomyopathy felt to be related to poorly controlled ventricular rate. However, maintenance of sinus rhythm even for a short time period is not assured. (See
         <a class="medical medical_review" href="/z/d/html/1062.html" rel="external">
          "Arrhythmia-induced cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/977.html" rel="external">
          "The management of atrial fibrillation in patients with heart failure", section on 'Rhythm control'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/977.html" rel="external">
          "The management of atrial fibrillation in patients with heart failure", section on 'Rhythm control'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Frequently, the only way to determine if subtle, nonspecific symptoms are attributable to AF is to restore SR to observe for symptom improvement. Symptom improvement may be delayed for several weeks due to markedly delayed recovery of atrial mechanical function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardioversion may be used in patients who have very infrequent, persistent episodes who do not respond to a pill-in-the-pocket approach. These individuals may cardioverted as needed from time to time. (See
         <a class="local">
          'Pill-in-the-pocket'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2829931687">
         <span class="h2">
          Unstable patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some hemodynamically unstable patients who manifest with signs or symptoms such as hypotension, altered mental status, or heart failure, if there is time to attempt ventricular rate slowing or to wait for possible spontaneous reversion to SR, cardioversion may be deferred. Emergency cardioversion should be performed if the patient is hemodynamically compromised due to an uncontrolled rapid ventricular rate or the lack of atrial contraction is thought to impair their cardiac output. If angina is felt to be related to the hemodynamic compromise or lack of atrial contraction with AF, we perform emergency cardioversion; however, the risk for a thromboembolic event needs to be considered. This includes patients with severe acute heart failure, ongoing myocardial ischemia, or hypotension. However, if hypotension occurs with a slow or moderate ventricular response (&lt;110 beats/min), other causes of hypotension should be sought, such as myocardial infarction, pulmonary embolism, sepsis, pericardial effusion/tamponade, or hypovolemia. (See
         <a class="medical medical_review" href="/z/d/html/1041.html" rel="external">
          "Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm", section on 'Adverse hemodynamics in AF'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H166080599">
         <span class="h1">
          REASONS NOT TO PERFORM CARDIOVERSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients in whom it is reasonable to avoid early cardioversion include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Those who are asymptomatic or minimally symptomatic, particularly those with multiple comorbidities, advanced age, or poor overall prognosis, where the risks of undergoing cardioversion and/or pharmacologic rhythm control may outweigh the benefits of restoring SR. Not performing cardioversion may also be appropriate in those with a low likelihood of long-term maintenance of SR, such as those with marked left atrial enlargement/dilatation, significant mitral regurgitation or stenosis, or those with florid hyperthyroidism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Those who cannot receive anticoagulation, if indicated, are generally not candidates for cardioversion unless the duration of AF is less than 48 hours. (See
         <a class="local">
          'Anticoagulation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation", section on 'AF duration uncertain or 48 or more hours'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Those with left atrial thrombus identified during a transesophageal echocardiogram or who have presented with a thrombotic event (eg, stroke or transient ischemia). (See
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation", section on 'Transesophageal echocardiography-based approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some experts would not pursue cardioversion in a person who has previously failed the procedure (ie, had only a brief period of sustained sinus rhythm following a prior cardioversion).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other reasons to consider not cardioverting include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Those where AF has been continuously present for more than one year [
         <a href="#rid1">
          1-6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Those with a left atrium that is markedly enlarged (atrial dimension &gt;6.0 cm, transthoracic echocardiographic biplane atrial volume index &gt;48 mL/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid6">
          6-11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Those with AF recurrence while taking adequate doses of appropriate antiarrhythmic drug therapy and who have recently undergone cardioversion. Drug refractory patients may have successful conversion to SR but are less likely to maintain SR long term. Cather ablation for AF may be a solution to maintaining SR for some patients in this situation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Those who do not or no longer respond to more than one antiarrhythmic drug are less likely to maintain SR with other drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Those for whom cardioversion with long-term maintenance of SR is likely to be unsuccessful if the underlying precipitant (eg, thyrotoxicosis, pericarditis, pneumonia, or mitral valve disease) has not been corrected prior to cardioversion.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H102941455">
         <span class="h1">
          PRECARDIOVERSION ISSUES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to cardioversion with either electrical energy or antiarrhythmic drug therapy in stable patients, decisions regarding rate control, timing, and anticoagulation need to be made.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8701631">
         <span class="h2">
          Ventricular rate control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a rapid resting ventricular response (&gt;100 beats per minute) usually need control of their ventricular rate to improve symptoms. This can be achieved by oral (and occasionally intravenous) administration of short-acting beta blockers or nondihydropyridine calcium channel antagonists, such as
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         or
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ]. In the acute setting, the target resting ventricular rate should usually be 80 to 100 beats per minute. (See
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8701646">
         <span class="h2">
          Anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients who will undergo cardioversion should be anticoagulated as soon as the decision is made to cardiovert or after assessment of their clinical thromboembolic risk based on their CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score. Issues related to anticoagulation around the time of cardioversion are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation", section on 'AF duration less than 48 hours'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1844964121">
         <span class="h2">
          Timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occasionally, hemodynamically unstable patients may need to be cardioverted urgently, without time to institute optimal oral anticoagulation (see
         <a class="local">
          'Anticoagulation'
         </a>
         above). For these patients who are not chronically anticoagulated but are candidates, intravenous heparin or low molecular weight heparin should be started as soon as possible, possibly with a loading dose of heparin prior to cardioversion due to more advanced transient impairment of atrial appendage mechanical function
         <em>
          after
         </em>
         cardioversion.
        </p>
        <p>
         For stable patients, the timing of elective cardioversion is determined in large part by the anticoagulant strategy chosen. If possible, patients with valvular and nonvalvular AF duration longer than 48 hours or of unknown duration should be therapeutically anticoagulated for at least four weeks or receive short-term anticoagulation followed by screening transesophageal echocardiography to exclude an atrial thrombus prior to cardioversion [
         <a href="#rid12">
          12
         </a>
         ]. Some of our authors use this approach if the duration is longer than 24 hours. Patients with a history of neurologic event, diabetes, and heart failure appear to be at very high risk for thromboembolism post-cardioversion, and four weeks of anticoagulation or short-term anticoagulation with transesophageal echocardiography should be considered [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H528718202">
         <span class="h2">
          Evaluation for underlying cause
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is useful to consider the potential for an underlying or precipitating cause, such as hyperthyroidism, but also acute pulmonary embolism, myopericarditis, pneumonia, pericarditis, or sepsis, though atrial fibrillation is rarely the sole manifestation of any of these other than hyperthyroidism. (See
         <a class="local">
          'Reasons not to perform cardioversion'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">
          "Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Triggers'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H413338">
         <span class="h1">
          ELECTRICAL VERSUS PHARMACOLOGIC CARDIOVERSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This section compares an electrical with a pharmacologic approach for cardioversion. However, patients who fail pharmacologic cardioversion are generally referred for electrical cardioversion. Thus, the comparison is really an electrical compared with a pharmacologic/electrical approach.
        </p>
        <p>
         For a
         <strong>
          first
         </strong>
         episode, electrical cardioversion is preferred in most cases. This is particularly true for younger patients (&lt;65 years) even if they have no symptoms. For
         <strong>
          other patients
         </strong>
         (not the first episode) who need to be cardioverted from AF to SR, either electrical or pharmacologic cardioversion (potentially followed by electrical cardioversion) is a reasonable approach. The choice between the two should take into account the strengths and weaknesses of each approach as well as patient preference. For most patients, we proceed directly to electrical cardioversion to avoid the potential of drug side effect and prolonged monitoring.
        </p>
        <p>
         Reasons to prefer electrical rather than pharmacologic cardioversion include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding drug side effects, including but not limited to transient hypotension or prolongation of the QTc interval.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding need for prolonged telemetric monitoring to screen for a proarrhythmic response. This can result in longer observation periods in the emergency department or procedural area.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some antiarrhythmic agents have the potential to convert AF to atrial flutter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Superior efficacy as compared with pharmacologic cardioversion.
        </p>
        <p>
        </p>
        <p>
         In contrast, potential benefits from a pharmacologic (rather than an electrical) approach include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding the risk(s) of sedation (required at the time of electrical cardioversion) (see
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias", section on 'Preparation and personnel'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing for drug tolerance, in the occasional patient (eg, someone with long-standing AF) in whom it has been decided to continue oral antiarrhythmic drug therapy (see
         <a class="local">
          'Preprocedural antiarrhythmic drugs'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Studies comparing the two approaches are somewhat limited.
        </p>
        <p>
         Mortality outcomes following electrical and pharmacologic cardioversion were similar in an observational cohort of 7175 patients from a large anticoagulation registry [
         <a href="#rid14">
          14
         </a>
         ]. There were 2427 (34 percent) patients who received pharmacological cardioversion and 4748 (66 percent) who received electrical cardioversion. During one-year follow-up, event rates (per 100 patient years) for mortality in patients who received electrical and pharmacological cardioversion were 1.36 (1.13 to 1.64) and 1.70 (1.35 to 2.14), respectively.
        </p>
        <p>
         In the RAFF2 trial, 396 patients with acute AF were randomly assigned to pharmacologic cardioversion with intravenous
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         or placebo followed by electrical cardioversion, if necessary [
         <a href="#rid15">
          15
         </a>
         ]. The primary outcome of conversion to normal SR for at least 30 minutes at any time after randomization and up to a point immediately after three shocks occurred with equal frequency in the two groups (96 versus 92 percent, respectively; p = 0.07). After procainamide infusion, 52 percent of patients converted (median time of 23 minutes), therefore not requiring subsequent electrical cardioversion. RAFF2 demonstrates that it is feasible for patients to be rapidly cardioverted with medical therapy in the emergency department, resolving their acute symptoms and enabling discharge home.
        </p>
        <p>
         However, we do not anticipate adoption of intravenous
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         in this setting due to the additional time required for chemical cardioversion compared with electrical cardioversion and the general lack of familiarity and experience with procainamide and its potential side effects by emergency department clinicians and general cardiologists. Further, the drug has a substantial half-life, making the risk of torsades de pointes due to early discharge problematic.
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          Ibutilide
         </a>
         is an antiarrhythmic drug that is more familiar to most clinicians caring for these patients and more likely to be chosen in this setting if an initial pharmacologic approach is attempted. (See
         <a class="local">
          'Specific antiarrhythmic drugs'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8701654">
         <span class="h1">
          ELECTRICAL CARDIOVERSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrical cardioversion of AF is a commonly performed medical procedure with a high success rate and a low complication rate when performed in the setting of anticoagulation. (See
         <a class="local">
          'Arrhythmic complications'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation", section on 'Rationale for anticoagulation'
         </a>
         .)
        </p>
        <p>
         The overall immediate success rate of electrical cardioversion is greater than 90 percent [
         <a href="#rid4">
          4,5,7-10,16,17
         </a>
         ]. However, the overall success rate falls as the AF duration increases and early recurrences are possible.
        </p>
        <p class="headingAnchor" id="H8701669">
         <span class="h2">
          Preprocedural antiarrhythmic drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients who undergo their first direct current cardioversion do not receive pretreatment with antiarrhythmic drugs. This is particularly true for unstable and other patients who need immediate restoration of SR. Pretreatment with antiarrhythmic drugs may also be omitted in patients in whom the potential for drug-induced arrhythmias is a concern.
        </p>
        <p>
         The following are reasons to consider initiation of antiarrhythmic drug therapy prior to electrical cardioversion:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To increase the likelihood of successful cardioversion [
         <a href="#rid1">
          1
         </a>
         ].
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         seem to decrease the cardioversion energy requirement and may be helpful in refractory patients. (See
         <a class="local">
          'Electrical versus pharmacologic cardioversion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To prevent recurrent episodes of AF soon after cardioversion.
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          Ibutilide
         </a>
         or
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         may be useful in preventing early recurrences of AF after cardioversion, particularly if it is of recent onset [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To allow for an evaluation of tolerability of one or more drugs. For those patients in whom a decision has been made to attempt the long-term maintenance of SR with antiarrhythmic drug therapy, we believe it is reasonable to preferentially select an agent for cardioversion that can also be used for long-term maintenance of SR (such as
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         , or
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To potentially avoid the need for intravenous sedation and subsequent electrical cardioversion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with recurrent AF soon after (&lt;few months) prior direct current cardioversion.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8701684">
         <span class="h2">
          Procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         A detailed discussion of electrical cardioversion is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/975.html" rel="external">
          "Basic principles and technique of external electrical cardioversion and defibrillation"
         </a>
         .)
        </p>
        <p>
         The following are a few important points:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If possible, the patient should be fasting for at least six hours. Oxygen saturation and electrolytes (particularly serum potassium) should be close to normal and anticoagulation status should be reviewed (anticoagulation status is crucial to prevent thromboembolism in the week after conversion; the need for and the type of anticoagulation depends on the patient’s clinical presentation as discussed elsewhere), and drug levels, when measured, should be within the therapeutic range.
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         need not be withheld unless digitalis toxicity is suspected [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/319.html" rel="external">
          "Digitalis (cardiac glycoside) poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrical cardioversion, synchronized to the QRS complex, should be performed while the patient is under the influence of procedural sedation and is having blood pressure, heart rate, oxygen saturation, and carbon dioxide capnography monitored. Generally, cardioversion should be done in a situation where airway equipment and airway expertise are present. (See
         <a class="medical medical_review" href="/z/d/html/264.html" rel="external">
          "Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrical cardioversion is very rarely associated with complications such as thromboembolism, respiratory distress due to acute heart failure, myocardial necrosis, skin burns, transient ventricular dysfunction, and transient arrhythmias including bradycardia. These are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias", section on 'Complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3499817310">
         <span class="h2">
          Postprocedural considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cardioversions take place without any significant adverse events. However, the following should be kept in mind.
        </p>
        <p class="headingAnchor" id="H8701706">
         <span class="h3">
          Hemodynamic changes after reversion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Left ventricular systolic function often improves and may normalize after achievement of SR, although it may take months for this to happen. In one study, left ventricular function improved soon after the restoration of SR, a change that was attributed to the reduction in heart rate and return of atrial mechanical contraction [
         <a href="#rid21">
          21
         </a>
         ]. Atrial contractility improves more slowly (atrial "stunning”) when the duration of AF prior to cardioversion is prolonged [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/981.html" rel="external">
          "Mechanisms of thrombogenesis in atrial fibrillation", section on 'Atrial stunning after cardioversion'
         </a>
         .)
        </p>
        <p>
         In uncommon instances, there can be ventricular "stunning." In these rare cases, there can be acute pulmonary edema after cardioversion. (See
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias", section on 'Myocardial dysfunction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8701722">
         <span class="h3">
          Recurrence of AF after cardioversion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The recurrence rate of AF after electrical cardioversion can be high, especially in patients with prior recurrences, a large left atrium, underlying structural disease, and a history of heart failure. There are times when it is appropriate to start an antiarrhythmic drug before cardioversion to lower the risk of recurrence soon after cardioversion. For the first attempt, however, especially if the heart is normal and there is no heart failure, a cardioversion without an antiarrhythmic is reasonable, particularly if maintenance antiarrhythmic therapy is not planned [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         The timing of AF recurrence was evaluated in a review of 61 patients who had daily electrocardiographic recordings using transtelephonic monitoring: 57 percent had recurrent AF during the first month after cardioversion, with a peak incidence during the first five days [
         <a href="#rid24">
          24
         </a>
         ]. This is one of the reasons that post-cardioversion anticoagulation should be used independently of CHADS
         <sub>
          2
         </sub>
         or CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score, as this may obviate the need for a transesophageal echocardiogram or an additional month of anticoagulation prior to another cardioversion.
        </p>
        <p>
         Electrical cardioversion may be repeated if AF recurs acutely in patients who have not been pretreated with antiarrhythmic therapy. In such patients or those in whom cardioversion fails, the combination of an atrioventricular (AV) nodal blocker plus intravenous loading with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         , or
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         , or oral dosing with
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         may restore SR pharmacologically.
        </p>
        <p>
         If the AF persists, electrical cardioversion may be performed and if successful, the patient may be placed on long-term antiarrhythmic therapy. (See
         <a class="local">
          'Pharmacologic cardioversion'
         </a>
         below.)
        </p>
        <p>
         A separate issue is whether to perform repeat cardioversion for later recurrence. One study has shown that two repeat cardioversions increase the likelihood of maintaining SR long-term [
         <a href="#rid25">
          25
         </a>
         ]. However, an important consideration is the time interval between AF episodes. In both of the above reports, a third cardioversion for recurrent AF was performed within seven days of the second cardioversion. Repeated cardioversion may be a reasonable approach for patients with AF that recurs after a longer duration of SR (eg, years). It is most likely to be successful in younger patients with fair exercise tolerance and AF duration of less than three years [
         <a href="#rid26">
          26
         </a>
         ]. Repeat cardioversion or nonpharmacologic therapy (catheter ablation of AF or AV nodal ablation) may be necessary in patients who remain symptomatic when in recurrent AF.
        </p>
        <p class="headingAnchor" id="H528717161">
         <span class="h3">
          Arrhythmic complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bradyarrhythmias are occasionally seen after electrical cardioversion, especially when patients are being treated with drugs to control the rate in AF, in older patients with tachycardia-bradycardia syndrome, and those with known preexisting bradycardia; ventricular tachyarrhythmias are rare but torsades de pointes can occur in patients treated with class III antiarrhythmics, especially in the first 24 hours after cardioversion and especially if there is bradycardia after cardioversion. In a retrospective study of 6906 cardioversions of acute AF in 2868 patients, 63 patients had bradyarrhythmias (51 episodes of asystole &gt;5 seconds and 12 episodes of bradycardia with heart rate &lt;40 bpm) [
         <a href="#rid27">
          27
         </a>
         ]. No episodes of ventricular arrhythmia requiring intervention were reported.
        </p>
        <p>
         Patients with sinus or AV node dysfunction, as in the tachycardia-bradycardia syndrome, are at higher risk for prolonged sinus pauses and bradycardia if AF is converted without a backup pacemaker. Nevertheless, the hemodynamic benefit from cardioversion may be sufficient to warrant restoration of SR with control of the atrial rate and/or AV conduction with a pacemaker. Physiologic pacing in patients with sinus node dysfunction and SR appears to decrease the likelihood of recurrent AF, especially if the initiation of AF episodes is bradycardia dependent [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/940.html" rel="external">
          "Sinus node dysfunction: Epidemiology, etiology, and natural history"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1072.html" rel="external">
          "Sinus node dysfunction: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8701755">
         <span class="h1">
          PHARMACOLOGIC CARDIOVERSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         As discussed above, we generally prefer electrical cardioversion to pharmacologic cardioversion in most patients.(See
         <a class="local">
          'Electrical versus pharmacologic cardioversion'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          Flecainide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         , and, to a lesser degree,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         have efficacy for pharmacologic conversion of AF. Of these, we prefer flecainide or propafenone unless there is evidence for coronary artery disease, left ventricular systolic dysfunction, or the duration of AF is greater than seven days, in which case dofetilide, or to a lesser degree, amiodarone or ibutilide have some role for medical conversion. None of these drugs is as efficacious as electrical cardioversion. In order to avoid side effects and proarrhythmia, we do not use two or more antiarrhythmic drugs at the same time.
        </p>
        <p>
         Structural heart disease is a contraindication to the use of some of the antiarrhythmic drugs. For the purpose of this topic, we define it as any condition in which there is a deviation in the size, shape, function, or structure of the atria or ventricles (such as left ventricular hypertrophy or dilated cardiomyopathy). This also includes coronary artery disease in the absence of left ventricular dysfunction. The definition does not include processes that alter the electrical properties of the heart, such as electrical activation, conduction, automaticity, or refractoriness.
        </p>
        <p class="headingAnchor" id="H3024804454">
         <span class="h2">
          Specific antiarrhythmic drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following antiarrhythmic drugs have been used to cardiovert patients in AF:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          Flecainide
         </a>
         is a very effective antiarrhythmic drug for the pharmacologic conversion of a patient with AF of short (&lt;24 hours) duration. Flecainide should not be used in patients with structural heart disease, particularly those with left ventricular systolic dysfunction or with coronary artery disease. (See
         <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">
          "Major side effects of class I antiarrhythmic drugs"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intravenous
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         (2 mg/kg over 10 minutes) acutely reverts recent onset AF in 67 to 92 percent of patients within six hours and is more effective than
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         , and
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . The intravenous preparation is not available in the United States. An oral dose of 200 to 300 mg has also been used.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A single, large oral dose of
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         (100 to 400 mg) is effective for AF reversion [
         <a href="#rid29">
          29,30
         </a>
         ]. One study randomly assigned 79 patients to intravenous or large oral dose of flecainide. The rate of reversion to SR was similar at two hours (64 versus 68 percent for oral drug) and eight hours after treatment (72 versus 75 percent); however, the mean time to reversion was shorter with intravenous flecainide (52 versus 110 minutes) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          Propafenone
         </a>
         is significantly more effective in paroxysmal as opposed to persistent AF, with rates likely approaching those seen with
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         . As with flecainide, we do not recommend propafenone in patients with structural heart disease, particularly those with left ventricular systolic dysfunction or coronary artery disease. (See
         <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">
          "Major side effects of class I antiarrhythmic drugs"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intravenous
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         (2 mg/kg over 10 to 20 minutes) is used in Europe for the acute termination of AF. Conversion rates of 23 to 54 percent in patients with AF of variable duration have been reported [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Oral
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         can be given as a large dose of 450 to 600 mg. A single oral loading dose reverted AF in 56 to 83 percent of patients, depending upon the duration of AF, in one study [
         <a href="#rid34">
          34,35
         </a>
         ]. The administration of propafenone prior to electrical cardioversion does not alter the energy requirements for, or the success rate of, cardioversion [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          Dofetilide
         </a>
         has primarily been studied for the medical conversion of persistent AF. Dofetilide has not been directly compared with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or
         <a class="drug drug_general" data-topicid="116881" href="/z/d/drug information/116881.html" rel="external">
          vernakalant
         </a>
         . Its principal use is to help maintain SR, rather than to be used for cardioversion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It has been used successfully in patients with structural heart disease. As an oral agent, it is rarely used solely for the purpose of cardioversion. It can be started prior to anticipated electrical cardioversion to help maintain SR shortly after either electrical or spontaneous cardioversion, or in those patients in whom it is chosen for the long-term maintenance of sinus rhythm. (See
         <a class="medical medical_review" href="/z/d/html/1033.html" rel="external">
          "Clinical use of dofetilide"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          Dofetilide
         </a>
         is more effective than placebo for the conversion of persistent AF to SR, particularly at a dose of 500 mcg twice daily [
         <a href="#rid37">
          37-39
         </a>
         ]. As an example, the SAFIRE-D study randomized 325 patients (including 60 percent with structural heart disease) with AF (n = 277) or atrial flutter (n = 48) to oral therapy with 125, 250, and 500 mcg twice daily [
         <a href="#rid37">
          37
         </a>
         ]. Overall conversion rates were 6, 9.8, and 30 percent, respectively. Among patients who convert with dofetilide, successful conversion occurred in 70 percent within 24 hours, while 91 percent converted within 36 hours. Postmarket uncontrolled trials have suggested that oral dofetilide is useful in the medical conversion of persistent AF in up to 60 percent of patients [
         <a href="#rid39">
          39
         </a>
         ]. Dofetilide also appears safe and efficacious in the setting of heart failure (including patients with AF); this is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1033.html" rel="external">
          "Clinical use of dofetilide", section on 'Heart failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          Dofetilide
         </a>
         has the disadvantage of requiring the patient to be hospitalized, as it can cause nonsustained ventricular tachycardia (VT), torsades de pointes, or sudden death [
         <a href="#rid40">
          40,41
         </a>
         ]. In the SAFIRE-D trial, the incidence of torsades de pointes was 1.2 percent [
         <a href="#rid37">
          37
         </a>
         ]. This risk is minimized by dosing based on the creatinine clearance and avoidance of other drugs that may cause torsades de pointes. Initiation of dofetilide is required to be in-hospital, under telemetry conditions by a doctor certified in its use, with a total of at least six dosages given before discharge. (See
         <a class="medical medical_review" href="/z/d/html/1033.html" rel="external">
          "Clinical use of dofetilide", section on 'Protocol for administration'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         (either oral or intravenous) is not particularly effective for cardioversion (though is effective for maintenance of SR postcardioversion). If reversion to SR occurs it does so several hours later than with
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         , and
         <a class="drug drug_general" data-topicid="116881" href="/z/d/drug information/116881.html" rel="external">
          vernakalant
         </a>
         [
         <a href="#rid42">
          42-52
         </a>
         ]. Intravenous amiodarone may be more effective in converting AF after it has been given for hours and days. Oral amiodarone requires long-term loading and is effective in converting about 25 percent of patients with persistent AF to SR after six weeks of loading. Thus, we do not recommend it solely for the purpose of cardioversion. It is not approved by the US Food and Drug Administration for the treatment of AF. (See
         <a class="medical medical_review" href="/z/d/html/926.html" rel="external">
          "Amiodarone: Clinical uses"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         may occasionally have value before cardioversion in patients who will receive the drug long term for maintenance of SR and may be considered as adjunctive therapy to increase the likelihood of successful cardioversion in patients who are known to be refractory to electrical cardioversion or in those in whom there is a concern about early relapse. (See
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations", section on 'Summary and recommendations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intravenous
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is given at a dose of 150 mg over 10 minutes, with a subsequent infusion of 1 mg/minute for six hours, then 0.5 mg/minute for 18 hours or change to oral maintenance dosing (eg, 100 to 200 mg once daily) [
         <a href="#rid53">
          53
         </a>
         ]. It should be kept in mind that the drug will likely have a significant rate-slowing effect, which may be beneficial in some patients [
         <a href="#rid54">
          54
         </a>
         ]. A table on monitoring for adverse effects is available  (
         <a class="graphic graphic_table graphicRef126072" href="/z/d/graphic/126072.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="116881" href="/z/d/drug information/116881.html" rel="external">
          Vernakalant
         </a>
         <strong>
         </strong>
         is available in Europe and Canada in intravenous forms for the rapid conversion (50 percent conversion within 10 minutes) of recent onset AF (less than eight days’ duration for patients not undergoing surgery, and less than four days’ duration for post-cardiac surgery patients) to SR. This drug is not available in the United States. (See
         <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Vernakalant'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a 2019 systematic review and meta-analysis of nine trials (n = 1358) comparing
         <a class="drug drug_general" data-topicid="116881" href="/z/d/drug information/116881.html" rel="external">
          vernakalant
         </a>
         with placebo,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , or
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         [
         <a href="#rid55">
          55
         </a>
         ], significant methodological bias was found in four trials. The following was also found:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="116881" href="/z/d/drug information/116881.html" rel="external">
          Vernakalant
         </a>
         was superior to placebo for conversion within 90 minutes (50 percent conversion; risk ratio 5.15, 95% CI 2.24-11.84).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No significant difference in the rate of conversion was found comparing
         <a class="drug drug_general" data-topicid="116881" href="/z/d/drug information/116881.html" rel="external">
          vernakalant
         </a>
         with active drug (56 versus 24 percent; risk ratio 2.40, 95% CI 0.76-7.58).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          Ibutilide
         </a>
         , due to its propensity to prolong repolarization and the QT interval, has the potential to provoke torsades de pointes. Ibutilide is available only as an intravenous preparation (1 mg over 10 minutes and potentially repeated once after 20 minutes) and is useful for the acute reversion of AF [
         <a href="#rid56">
          56-58
         </a>
         ]. It has been used in patients with structural heart disease (but without heart failure). We use ibutilide very rarely in this setting. (See
         <a class="medical medical_review" href="/z/d/html/924.html" rel="external">
          "Therapeutic use of ibutilide"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In trials, the acute AF conversion rate is 28 to 51 percent.
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          Ibutilide
         </a>
         is more effective at converting atrial flutter to SR, with conversion rates of 50 to 75 percent. Ibutilide can work in acute situations of persistent AF and can be used (with caution) in patients with structural heart disease. However, while these rates seem low compared with
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         or
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         , ibutilide has not been directly compared with these other drugs. In addition, the average conversion times with ibutilide seem shorter than with flecainide and propafenone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Arrhythmia conversion occurred within a mean of 27 to 33 minutes after the start of the infusion [
         <a href="#rid57">
          57,58
         </a>
         ]. In comparative studies,
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         has been more effective for AF reversion than
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         (51 versus 21 percent and 32 versus 5 percent) [
         <a href="#rid59">
          59,60
         </a>
         ] or intravenous
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         (44 versus 11 percent) [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In four large series, the rate of torsades de pointes with
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         ranged between 3.6 and 8.3 percent [
         <a href="#rid56">
          56-58,60
         </a>
         ]. Sustained episodes of torsades de pointes, requiring cardioversion, were seen in 1.7 to 2.4 percent. In addition to polymorphic VT, nonsustained monomorphic VT occurred in an additional 3.2 to 3.6 percent of patients [
         <a href="#rid57">
          57,58
         </a>
         ]. Because of the risk of ventricular proarrhythmia, patients treated with ibutilide should be observed with continuous rhythm monitoring for at least four hours after the infusion or until the QTc interval has returned to baseline. Pretreatment with intravenous magnesium appears to minimize the risk of ibutilide-induced torsades de pointes without affecting the efficacy of conversion [
         <a href="#rid62">
          62
         </a>
         ]. Risk factors for the development of torsades de pointes with ibutilide are heart failure, baseline increase in QTc interval, and low potassium or magnesium. Electrolytes should be checked and normalized before cardioversion with ibutilide.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We occasionally use
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         in patients resistant to electrical cardioversion and in patients for whom anesthesia, in conjunction with direct current cardioversion, is not readily available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The recommended dose varies with patient size. For patients weighing less than 60 kg, the recommended dose is 0.01 mg/kg infused over 10 minutes. If the arrhythmia does not terminate 10 minutes after the end of the infusion, a second bolus (same dose over 10 minutes) can be given. For patients weighing more than 60 kg, the recommended starting intravenous dose is 1 mg over 10 minutes. If AF does not terminate 10 minutes after the end of the infusion, a second bolus of 1 mg over 10 minutes can be given. Most patients studied have had arrhythmia for less than 90 days. Efficacy has not been proven with an AF duration exceeding 90 days. We do not use
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         in combination with other antiarrhythmic medications.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8701822">
         <span class="h2">
          Less effective or ineffective drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several medications such as
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         and
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         are no longer used for cardioversion as most of the agents presented above have greater efficacy or fewer side effects or both.
        </p>
        <p>
         The following antiarrhythmic drugs are not particularly effective for the restoration of SR:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         – Oral sotalol is less effective than
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         [
         <a href="#rid63">
          63
         </a>
         ] and equally effective to
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         for chemical cardioversion of AF (27 percent at 28 days) [
         <a href="#rid64">
          64
         </a>
         ]. Intravenous sotalol is less effective than intravenous
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         or
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         for reversion of AF [
         <a href="#rid61">
          61,65
         </a>
         ]. Thus, we do not recommend either form for chemical cardioversion of AF. (See
         <a class="medical medical_review" href="/z/d/html/925.html" rel="external">
          "Clinical uses of sotalol"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          Dronedarone
         </a>
         – We do not recommend dronedarone for the restoration of SR in patients with AF since conversion rates are very low [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rate-control drugs
         </strong>
         such as
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         , nondihydropyridine calcium channel blockers (eg,
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         or
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         ), and beta blockers have not been effective in restoring SR in placebo-controlled studies. Many clinicians overestimate the effectiveness (for cardioversion) of these agents [
         <a href="#rid1">
          1,67-72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2740977855">
         <span class="h2">
          Pill-in-the-pocket
         </span>
         <span class="headingEndMark">
          —
         </span>
         A "pill-in-the-pocket" approach with either
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         (&lt;70 kg: 200 mg; may not repeat in ≤24 hours; ≥70 kg: 300 mg; may not repeat in ≤24 hours) or
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         can be used to terminate out-of-hospital paroxysmal AF of short duration after these drugs have been shown to be efficacious and safe in a monitored setting. In this approach, we have the patient take a
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         or a beta blocker 30 minutes or more (if they are not on chronic AV nodal blocker) before the oral antiarrhythmic drug to prevent a rapid ventricular rate should conversion to atrial flutter occur. Some of our contributors prefer the patient to be observed in the emergency department (or potentially during inpatient hospitalization) the first time the "pill-in-the-pocket" approach is taken so that monitoring of safety and efficacy occurs.
        </p>
        <p>
         Some authors also instruct their patients to begin a direct-acting oral anticoagulants (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]) at the time of the beta blocker/
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         so as to decrease the risk of thrombus formation should the patient not convert to SR in the subsequent 48 hours and to prophylaxis for thrombus formation during the transient periconversion period of atrial appendage mechanical dysfunction.
        </p>
        <p class="headingAnchor" id="H528717603">
         <span class="h1">
          MAINTENANCE ANTIARRHYTHMIC DRUG THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         After successful electrical cardioversion, antiarrhythmic drugs increase the likelihood of long-term maintenance of SR [
         <a href="#rid1">
          1
         </a>
         ]. The use of antiarrhythmic drugs to maintain SR is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"
         </a>
         .)
        </p>
        <p>
         We do not generally recommend maintenance antiarrhythmic drugs after electrical cardioversion in patients with their
         <strong>
          first
         </strong>
         episode of non-valvular AF, particularly those at low risk for recurrence (eg, short-duration AF, normal or only mildly increased left atrial size, normal left ventricular systolic function, absence of valvular dysfunction) or those with a transient cause (eg, pericarditis, pulmonary embolism, and corrected or treated hyperthyroidism) [
         <a href="#rid73">
          73
         </a>
         ]. (See
         <a class="local">
          'Recurrence of AF after cardioversion'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H952133456">
         <span class="h1">
          RECOMMENDATIONS OF OTHERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Societal guidelines are available [
         <a href="#rid53">
          53,74-76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H728582171">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">
          "Society guideline links: Atrial fibrillation"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H872637764">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unstable patients
         </strong>
         – For the uncommon patient who is hemodynamically unstable or has angina due to AF and is at low risk for thromboembolism, we recommend urgent electrical cardioversion rather than no cardioversion (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). Precardioversion intravenous heparin bolus may be beneficial for prevention of thromboembolism due to postcardioversion atrial appendage dysfunction, but its efficacy has not been studied. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stable patients
         </strong>
         – Most patients with AF do not need emergency or even urgent cardioversion, as rate slowing will often improve symptoms. We also attempt to defer cardioversion to allow for initiation of anticoagulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For select, stable patients with nonvalvular AF, the restoration of sinus rhythm (SR) with either electrical or pharmacologic cardioversion is necessary or reasonable (see
         <a class="local">
          'Ventricular rate control'
         </a>
         above and
         <a class="local">
          'Indications'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptomatic, first episode of AF
         </strong>
         – For most symptomatic patients with new onset/first episode of AF, we suggest an attempt at cardioversion, as opposed to no attempt (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In patients who do have factors that predict a high likelihood of success of electrical cardioversion, and in whom long-term maintenance antiarrhythmic drug therapy is not planned, we suggest electrical instead of pharmacologic cardioversion (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Reasons not to perform cardioversion'
         </a>
         above and
         <a class="local">
          'Electrical versus pharmacologic cardioversion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In such patients who are older or have multiple medical comorbidities, it is reasonable to avoid cardioversion if the symptoms can be minimized and pharmacologic ventricular rate control is achieved; the approach needs to be individualized.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients who fail long-term rate control
         </strong>
         – For patients in whom a long-term rate control strategy has failed due to persistent symptoms, a rhythm control strategy involving cardioversion is reasonable.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Infrequent episodes of AF
         </strong>
         – Periodic electrical cardioversion is an option for patients with infrequent episodes of AF that do not spontaneously convert, including those being managed with a rhythm control strategy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Roles of rate control and anticoagulation
         </strong>
         – Most patients in whom cardioversion is chosen will need the ventricular rate controlled and the need for anticoagulation assessed prior to cardioversion. (See
         <a class="local">
          'Ventricular rate control'
         </a>
         above and
         <a class="local">
          'Anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiarrhythmic drugs
         </strong>
         – These may be initiated prior to electrical cardioversion to increase the likelihood of a successful electrical cardioversion, to increase the likelihood of maintaining SR in the hours after cardioversion, or as the first step in a plan for long-term antiarrhythmic therapy. (See
         <a class="local">
          'Preprocedural antiarrhythmic drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with AF and no structural heart disease (including no evidence of coronary artery disease) for whom pharmacologic cardioversion is chosen, we suggest either
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         or
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         rather than other antiarrhythmic drugs (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). The choice between these two drugs should be influenced by the practitioner’s experience and the clinical situation. (See
         <a class="local">
          'Pharmacologic cardioversion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3789764198">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Leonard Ganz, MD, FHRS, FACC, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Naccarelli GV, Dell'Orfano JT, Wolbrette DL, et al. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol 2000; 85:36D.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falk RH. Atrial fibrillation. N Engl J Med 2001; 344:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Resnekov L, McDonald L. Appraisal of electroconversion in treatment of cardiac dysrhythmias. Br Heart J 1968; 30:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elhendy A, Gentile F, Khandheria BK, et al. Predictors of unsuccessful electrical cardioversion in atrial fibrillation. Am J Cardiol 2002; 89:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher MM, Guo XH, Poloniecki JD, et al. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol 2001; 38:1498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frick M, Frykman V, Jensen-Urstad M, et al. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 2001; 24:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dittrich HC, Erickson JS, Schneiderman T, et al. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry WL, Morganroth J, Pearlman AS, et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976; 53:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundström T, Rydén L. Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand 1988; 223:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalzell GW, Anderson J, Adgey AA. Factors determining success and energy requirements for cardioversion of atrial fibrillation. Q J Med 1990; 76:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchett EL. Management of atrial fibrillation. N Engl J Med 1992; 326:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg A, Khunger M, Seicean S, et al. Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset. JACC Clin Electrophysiol 2016; 2:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Airaksinen KE, Grönberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol 2013; 62:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pope MK, Hall TS, Schirripa V, et al. Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. BMJ 2021; 375:e066450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stiell IG, Sivilotti MLA, Taljaard M, et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. Lancet 2020; 395:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartzman D, Musley SK, Swerdlow C, et al. Early recurrence of atrial fibrillation after ambulatory shock conversion. J Am Coll Cardiol 2002; 40:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurevitz OT, Ammash NM, Malouf JF, et al. Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter. Am Heart J 2005; 149:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95:1945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Simone A, Stabile G, Vitale DF, et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999; 34:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann DL, Maisel AS, Atwood JE, et al. Absence of cardioversion-induced ventricular arrhythmias in patients with therapeutic digoxin levels. J Am Coll Cardiol 1985; 5:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alam M, Thorstrand C. Left ventricular function in patients with atrial fibrillation before and after cardioversion. Am J Cardiol 1992; 69:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994; 23:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schilling RJ. Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs. Heart 2010; 96:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tieleman RG, Van Gelder IC, Crijns HJ, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998; 31:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertaglia E, D'Este D, Zerbo F, et al. Success of serial external electrical cardioversion of persistent atrial fibrillation in maintaining sinus rhythm; a randomized study. Eur Heart J 2002; 23:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gelder IC, Crijns HJ, Tieleman RG, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156:2585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grönberg T, Nuotio I, Nikkinen M, et al. Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study. Europace 2013; 15:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saksena S, Prakash A, Hill M, et al. Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. J Am Coll Cardiol 1996; 28:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992; 70:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004; 351:2384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alp NJ, Bell JA, Shahi M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart 2000; 84:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997; 79:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conti A, Del Taglia B, Mariannini Y, et al. Management of patients with acute atrial fibrillation in the ED. Am J Emerg Med 2010; 28:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001; 37:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Botto GL, Bonini W, Broffoni T, et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? Pacing Clin Electrophysiol 1996; 19:1939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianconi L, Mennuni M, Lukic V, et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol 1996; 28:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102:2385.
          </a>
         </li>
         <li class="breakAll">
          Greenbaum RA, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study (Abstr). Circulation 1998; 98(17 Suppl): 1633.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banchs JE, Wolbrette DL, Samii SM, et al. Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter. J Interv Card Electrophysiol 2008; 23:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mounsey JP, DiMarco JP. Cardiovascular drugs. Dofetilide. Circulation 2000; 102:2665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abraham JM, Saliba WI, Vekstein C, et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 2015; 8:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vietti-Ramus G, Veglio F, Marchisio U, et al. Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. Int J Cardiol 1992; 35:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1990; 65:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1996; 27:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Marcos FJ, García-Garmendia JL, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peuhkurinen K, Niemelä M, Ylitalo A, et al. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol 2000; 85:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanc JJ, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol 1999; 84:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352:1861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tieleman RG, Gosselink AT, Crijns HJ, et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vardas PE, Kochiadakis GE, Igoumenidis NE, et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 2000; 117:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998; 81:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre WF, Healey JS, Bhatnagar AK, et al. Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis. Europace 2019; 21:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996; 28:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abi-Mansour P, Carberry PA, McCowan RJ, et al. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J 1998; 136:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998; 31:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation 1997; 96:4298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998; 79:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patsilinakos S, Christou A, Kafkas N, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol 2010; 106:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira E, Sunderji R, Gin K. Is oral sotalol effective in converting atrial fibrillation to sinus rhythm? Pharmacotherapy 1997; 17:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chevalier P, Durand-Dubief A, Burri H, et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003; 41:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998; 81:1450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iannone P, Haupt E, Flego G, et al. Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines. JAMA Intern Med 2014; 174:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 1997; 18:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts SA, Diaz C, Nolan PE, et al. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol 1993; 72:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson S, Blanski L, Byrd RC, et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group. Am Heart J 1986; 111:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med 1981; 94:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1989; 63:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140:e125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42:373.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1025 Version 69.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10822039" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11287978" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5718988" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Appraisal of electroconversion in treatment of cardiac dysrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11779532" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Predictors of unsuccessful electrical cardioversion in atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11691530" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11288971" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2909999" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/128423" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Relation between echocardiographically determined left atrial size and atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3348103" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Chronic atrial fibrillation. Long-term results of direct current conversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2236476" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Factors determining success and energy requirements for cardioversion of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1560803" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Management of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29759870" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23850908" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34706884" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32007169" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12103261" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Early recurrence of atrial fibrillation after ambulatory shock conversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15846271" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9107184" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Verapamil reduces tachycardia-induced electrical remodeling of the atria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10483964" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3973290" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Absence of cardioversion-induced ventricular arrhythmias in patients with therapeutic digoxin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1536123" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Left ventricular function in patients with atrial fibrillation before and after cardioversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8294679" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19910286" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9426036" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12242072" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Success of serial external electrical cardioversion of persistent atrial fibrillation in maintaining sinus rhythm; a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8951302" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23687124" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8772757" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1615873" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15575054" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10862585" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9052343" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20825922" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Management of patients with acute atrial fibrillation in the ED.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11216976" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8945073" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8772759" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11067793" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11067793" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18688699" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11085972" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Cardiovascular drugs. Dofetilide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26063741" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1563883" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2178386" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8609324" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21232669" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11053705" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10728951" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10569658" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15872201" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Amiodarone versus sotalol for atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9024736" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19948506" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10858380" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9514456" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31292622" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8752805" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8840852" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9778066" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9581743" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9416896" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10078083" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20723644" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9399605" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Is oral sotalol effective in converting atrial fibrillation to sinus rhythm?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12535819" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9645896" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24535046" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9129897" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8362772" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2868645" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7447203" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2650517" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9973007" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22922413" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682348" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30686041" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
